Search research articles
Contact Us
Filters
Showing results (141-150 of 260) with videos related to
Page
of 26
Sort By:
Cancer Discovery
|
April 12, 2022
Precision Combination Therapies Based on Recurrent Oncogenic Coalterations
Xubin Li, Elisabeth K Dowling, Gonghong Yan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2021
ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate Cancer
Zhe Tang, Patrick G Pilié, Chuandong Geng, et al.
The Lancet. Respiratory Medicine
|
April 9, 2021
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study
Timothy A Yap, Kazuhiko Nakagawa, Nobukazu Fujimoto, et al.
Signal Transduction and Targeted Therapy
|
February 23, 2026
Concordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncology
Stephanie T Schmidt, Mehmet A Baysal, Siqing Fu, et al.
The Oncologist
|
March 26, 2025
Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis
Funda Meric-Bernstam, Aditya Bardia, Paolo Bossi, et al.
Oncotarget
|
December 22, 2017
High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy
Raquel Perez-Lopez, Desam Roda, Begona Jimenez, et al.
The Journal of Clinical Investigation
|
October 5, 2020
Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors
Lulu Wang, Lin Yang, Chen Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 4, 2010
Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors
Timothy A Yap, Laura Vidal, Jan Adam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 17, 2025
First-In-Human Phase 1/2a Study of the First-In-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Timothy A Yap, Jonathan W Goldman, Shaveta Vinayak, et al.
Cancer
|
October 8, 2016
A study of motivations and expectations of patients seen in phase 1 oncology clinics
Saoirse O Dolly, Eleftheria Kalaitzaki, Martina Puglisi, et al.
Page
of 26
Search research articles
Search
Showing results (141-150 of 260) with videos related to
Sort By:
Page
of 26
Cancer Discovery
|
April 12, 2022
Precision Combination Therapies Based on Recurrent Oncogenic Coalterations
Xubin Li, Elisabeth K Dowling, Gonghong Yan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2021
ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate Cancer
Zhe Tang, Patrick G Pilié, Chuandong Geng, et al.
The Lancet. Respiratory Medicine
|
April 9, 2021
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study
Timothy A Yap, Kazuhiko Nakagawa, Nobukazu Fujimoto, et al.
Signal Transduction and Targeted Therapy
|
February 23, 2026
Concordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncology
Stephanie T Schmidt, Mehmet A Baysal, Siqing Fu, et al.
The Oncologist
|
March 26, 2025
Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis
Funda Meric-Bernstam, Aditya Bardia, Paolo Bossi, et al.
Oncotarget
|
December 22, 2017
High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy
Raquel Perez-Lopez, Desam Roda, Begona Jimenez, et al.
The Journal of Clinical Investigation
|
October 5, 2020
Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors
Lulu Wang, Lin Yang, Chen Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 4, 2010
Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors
Timothy A Yap, Laura Vidal, Jan Adam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 17, 2025
First-In-Human Phase 1/2a Study of the First-In-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Timothy A Yap, Jonathan W Goldman, Shaveta Vinayak, et al.
Cancer
|
October 8, 2016
A study of motivations and expectations of patients seen in phase 1 oncology clinics
Saoirse O Dolly, Eleftheria Kalaitzaki, Martina Puglisi, et al.
Page
of 26